Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 6—June 2005
Research

Integrating Escherichia coli Antimicrobial Susceptibility Data from Multiple Surveillance Programs

John M. Stelling*†Comments to Author , Karin Travers*, Ronald N. Jones‡§, Philip J. Turner¶, Thomas F. O'Brien*†, and Stuart B. Levy*§
Author affiliations: *Alliance for the Prudent Use of Antibiotics, Boston, Massachusetts, USA; †Brigham and Women's Hospital, Boston, Massachusetts, USA; ‡The Jones Group, North Liberty, Iowa, USA; §Tufts University, Boston, Massachusetts, USA; ¶AstraZeneca, Macclesfield, Cheshire, United Kingdom

Main Article

Figure 3

SENTRY results for antimicrobial agents tested in common with MYSTIC. Annual nonsusceptibility rates of Escherichia coli, 1997–2001. p<0.05. CAZ, ceftazidime; TZP, piperacillin/tazobactam; GEN, gentamicin; CIP, ciprofloxacin; TOB, tobramycin; FEP, cefepime.

Figure 3. . SENTRY results for antimicrobial agents tested in common with MYSTIC. Annual nonsusceptibility rates of Escherichia coli, 1997–2001. p<0.05. CAZ, ceftazidime; TZP, piperacillin/tazobactam; GEN, gentamicin; CIP, ciprofloxacin; TOB, tobramycin; FEP, cefepime.

Main Article

Page created: April 24, 2012
Page updated: April 24, 2012
Page reviewed: April 24, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external